Biotech Values

[mcbio]

Re: MNTA

So far as I know, Oppenhimer is the only house that thinks Teva's enox won't be approved within a few months. . . .

Then, MNTA might slowly ramp up into the anticipated date of a Markman ruling, which now seems to be in the first half of next year. . . .

So that means that MNTA is dead money until the Markman ruling.

Assuming the consensus is that Teva will get their approval for generic Lovenox by year end, if we get to end of 1Q11 and there's no approval for Teva, perhaps sentiment will start to shift that MNTA may be the only company to obtain the approval. I think there's the possibility we could see some strength in MNTA shares on that alone, irrespective of the Markman ruling.